The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: A noncontrolled study

Dermatology

Volumn 227, Issue 2, 2013, Pages 103-108

  Karadag, Ayse Serap ^a   Ertugrul, Derun Taner ^b   Kalkan, Goknur ^e   Bilgili, Serap Gunes ^f   Celik, Huseyin Tugrul ^d   Takci, Zennure ^c   Balahoroglu, Ragip ^f   Calka, Omer ^f  

^a ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^b Faculty of Medicine   (Turkey)

^c Kecioren Research and Training Hospital   (Turkey)

^d FATIH UNIVERSITY   (Turkey)

^e GAZIOSMANPASA UNIVERSITY   (Turkey)

^f YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Acitretin; Insulin resistance; Psoriasis; Retinol binding protein 4

Indexed keywords

ADIPONECTIN; C PEPTIDE; ETRETIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; PLACEBO; RETINOL BINDING PROTEIN 4;

ADULT; ARTICLE; BODY MASS; BODY SURFACE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; PSORIASIS VULGARIS; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ACITRETIN; ADIPONECTIN; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN; INSULIN RESISTANCE; LEPTIN; MALE; PSORIASIS; RETINOL-BINDING PROTEINS, PLASMA;

EID: 84888215947     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000351769     Document Type: Article

References (29)

1. Abdel Hay RM, Rashed LA. Association between the leptin gene 2548G/A polymorphism, the plasma leptin and the metabolic syndrome with psoriasis. Exp Dermatol 2011; 20: 715-719
2. Kawashima K, Torii K, Furuhashi T, Saito C, Nishio E, Nishida E, Shintani Y, Morita A. Phototherapy reduces serum resistin levels in psoriasis patients. Photodermatol Photoimmunol Photomed 2011; 27: 152-155
3. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-Analysis of observational studies. J Am Acad Dermatol 2013; 68: 654-662
4. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, Figueiredo A, Teixeira F, Castro E, Rocha-Pereira P, Santos-Silva A. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 1386-1394
5. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008; 159: 1207-1208
6. Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI, Steinsson JT, Elder JT, Valdimarsson H. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008; 159: 342-350
7. Takemura Y, Walsh K, Ouchi N. Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler Rep 2007; 9: 238-243
8. Aguilera CM, Gil-Campos M, Canete R, Gil A. Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome. Clin Sci (Lond) 2008; 114: 183-193
9. Lautamaki R, Ronnemaa T, Huupponen R, Lehtimaki T, Iozzo P, Airaksinen KE, Knuuti J, Nuutila P. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 2007; 56: 881-886
10. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, Figueiredo A, Teixeira F, Castro E, Rocha-Pereira P, Santos-Silva A. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci 2009; 55: 202-204
11. Chavarria N, Kato TS, Khan R, Chokshi A, Collado E, Akashi H, Takayama H, Naka Y, Farr M, Mancini D, Schulze PC. Increased levels of retinol binding protein 4 in patients with advanced heart failure correct after hemodynamic improvement through ventricular assist device placement. Circ J 2012; 76: 2148-2152
12. Ozdemir M, Yuksel M, Gokbel H, Okudan N, Mevlitoglu I. Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin. J Dermatol 2012; 39: 443-448
13. Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol 2012; 39: 212-218
14. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145: 379-382
15. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008; 159: 1331-1337
16. Preitner F, Mody N, Graham TE, Peroni OD, Kahn BB. Long-Term fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis. Am J Physiol Endocrinol Metab 2009; 297: E1420-E1429
17. Johansson H, Gandini S, Guerrieri-Gonzaga A, Iodice S, Ruscica M, Bonanni B, Gulisano M, Magni P, Formelli F, Decensi A. Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 2008; 68: 9512-9518
18. Koh IU, Jun HS, Choi JS, Lim JH, Kim WH, Yoon JB, Song J. Fenretinide ameliorates insulin resistance and fatty liver in obese mice. Biol Pharm Bull 2012; 35: 369-375
19. Corbetta S, Angioni R, Cattaneo A, Beck-Peccoz P, Spada A. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 2006; 154: 83-86
20. Kotnik P, Fischer-Posovszky P, Wabitsch M. RBP4: a controversial adipokine. Eur J Endocrinol 2011; 165: 703-711
21. Newcomer ME, Ong DE. Plasma retinol binding protein: structure and function of the prototypic lipocalin. Biochim Biophys Acta 2000; 1482: 57-64
22. Erikstrup C, Mortensen OH, Nielsen AR, Fischer CP, Plomgaard P, Petersen AM, Krogh-Madsen R, Lindegaard B, Erhardt JG, Ullum H, Benn CS, Pedersen BK. RBP-To-retinol ratio, but not total RBP, is elevated in patients with type 2 diabetes. Diabetes Obes Metab 2009; 11: 204-212
23. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-362
24. Munkhtulga L, Nagashima S, Nakayama K, Utsumi N, Yanagisawa Y, Gotoh T, Omi T, Kumada M, Zolzaya K, Lkhagvasuren T, Kagawa Y, Fujiwara H, Hosoya Y, Hyodo M, Horie H, Kojima M, Ishibashi S, Iwamoto S. Regulatory SNP in the RBP4 gene modified the expression in adipocytes and associated with BMI. Obesity (Silver Spring) 2010; 18: 1006-1014
25. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS. Plasma retinolbinding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006; 29: 2457-2461
26. Promintzer M, Krebs M, Todoric J, Luger A, Bischof MG, Nowotny P, Wagner O, Esterbauer H, Anderwald C. Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab 2007; 92: 4306-4312
27. Lee YH, Magkos F, Mantzoros CS, Kang ES. Effects of leptin and adiponectin on pancreatic beta-cell function. Metabolism 2011; 60: 1664-1672
28. Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U. Leptin, adiponectin, visfatin and retinolbinding protein-4-mediators of comorbidities in patients with psoriasis? Exp Dermatol 2012; 21: 43-47
29. Festuccia WT, Blanchard PG, Turcotte V, Laplante M, Sariahmetoglu M, Brindley DN, Deshaies Y. Depot-specific effects of the PPARgamma agonist rosiglitazone on adipose tissue glucose uptake and metabolism. J Lipid Res 2009; 50: 1185-1194